Evolving Resistance among Gram-positive Pathogens

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S48-S57

  Munita, Jose M ^a,e,g   Bayer, Arnold S ^c,d   Arias, Cesar A ^a,b,e,f  

^a Division of Infectious Diseases   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e International Center for Microbial Genomics   (Colombia)

^f UNIVERSIDAD EL BOSQUE   (Colombia)

^g UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

antimicrobial resistance; methicillin resistant; multidrug resistant; penicillin resistant; vancomycin resistant

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AVOPARCIN; BETA LACTAM; CARDIOLIPIN; CEFAZOLIN; CEFTAROLINE; CEFTOBIPROLE; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; RIBOSOME PROTEIN; TEDIZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; DRUG EFFECTS; GENETICS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; MICROBIOLOGY; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVOLUTION, MOLECULAR; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MUTATION;

EID: 84941595682     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ523     Document Type: Article

References (78)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed 9 March 2015.
2. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Available at: http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 4 March 2015.
3. Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbs Infect 2012; 14:573-83.
4. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
5. Bai AD, Showler A, Burry L, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother 2015; 70:1539-46.
6. Lee S, Kwon KT, Kim HI, et al. Clinical implications of cefazolin inoculum effect and beta-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist 2014; 20:568-74.
7. Nannini EC, Singh KV, Arias CA, Murray BE. In vivo effect of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin. Antimicrob Agents Chemother 2013; 57:4276-81.
8. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009; 119:2464-74.
9. Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillinresistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012; 67:1321-4.
10. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 2014; 69:2065-75.
11. Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in western Switzerland archived since 1998. Antimicrob Agents Chemother 2015; 59:1922-30.
12. Long SW, Olsen RJ, Mehta SC, et al. PBP2a mutations causing highlevel ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2014; 58:6668-74.
13. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2089-96.
14. Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012; 3:421-33.
15. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther 2014; 12:1221-36.
16. Rice LB, Bellais S, Carias LL, et al. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother 2004; 48:3028-32.
17. Galloway-Pena JR, Rice LB, Murray BE. Analysis of PBP5 of early U.S. isolates of Enterococcus faecium: sequence variation alone does not explain increasing ampicillin resistance over time. Antimicrob Agents Chemother 2011; 55:3272-7.
18. Murray BE, Mederski-Samaroj B. Transferable beta-lactamase: a new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983; 72:1168-71.
19. Clinical and Laboratory Standards Institute. MS100-22. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Vol. 32. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
20. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735-40.
21. Dagan R, Juergens C, Trammel J, et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. J Infect Dis 2015; 211:1144-53.
22. Dowson CG, Coffey TJ, Kell C, Whiley RA. Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae. Mol Microbiol 1993; 9:635-43.
23. Sibold C, Henrichsen J, Konig A, Martin C, Chalkley L, Hakenbeck R. Mosaic pbpX genes of major clones of penicillin-resistant Streptococcus pneumoniae have evolved from pbpX genes of a penicillin-sensitive Streptococcus oralis. Mol Microbiol 1994; 12:1013-23.
24. Hakenbeck R, Bruckner R, Denapaite D, Maurer P. Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae. Future Microbiol 2012; 7:395-410.
25. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycinresistant enterococci: is it time to divorce? J Antimicrob Chemother 2013; 68:731-42.
26. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012; 10:266-78.
27. Lebreton F, van Schaik W, McGuire AM, et al. Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains. MBio 2013; 4:e00534-13.
28. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42(suppl 1):S25-34.
29. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
30. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99-139.
31. Bae IG, Federspiel JJ, Miro JM, et al; International Collaboration on Endocarditis-Microbiology Investigators. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillinresistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355-66.
32. Parer S, Lotthe A, Chardon P, Poncet R, Jean-Pierre H, Jumas-Bilak E. An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit. Infect Control Hosp Epidemiol 2012; 33:167-74.
33. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 2014; 124:2836-40.
34. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Contribution of selected gene mutations to resistance in clinical isolates of vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:5845-51.
35. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-6.
36. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668-74.
37. Rossi F, Diaz L,Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014; 370:1524-31.
38. VIBATIV (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Available at: http://www.vibativ.com. Accessed 19 March 2015.
39. Durata Therapeutics US. Dalvance (dalbavancin for injection), prescribing information. Available at: http://www.dalvance.com/. Accessed 30 May 2015.
40. The Medicines Company. Orbactic (oritavancin for injection), prescribing information. Available at: http://www.orbactiv.com/. Accessed 30 March 2015.
41. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70:859-86.
42. Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012; 54(suppl 3):S233-8.
43. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46:3334-6.
44. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64:1506-14.
45. Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014; 17:1-12.
46. Bonilla H, Huband MD, Seidel J, et al. Multicity outbreak of linezolidresistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 2010; 51:796-800.
47. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821-5.
48. LaMarre JM, Locke JB, Shaw KJ, Mankin AS. Low fitness cost of the multidrug resistance gene cfr. Antimicrob Agents Chemother 2011; 55:3714-9.
49. Diaz L, Kontoyiannis DP, Panesso D, et al. Dissecting the mechanisms of linezolid resistance in a Drosophila melanogaster infection model of Staphylococcus aureus. J Infect Dis 2013; 208:83-91.
50. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 2014; 58(suppl 1):S35-42.
51. Baos E, Candel FJ, Merino P, Pena I, Picazo JJ. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76:325-9.
52. Locke JB, HilgersM, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009; 53:5265-74.
53. Mendes RE, Hogan PA, Streit JM, Jones RN, Flamm RK. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 2014; 69:1582-8.
54. Diaz L, Kiratisin P, Mendes RE, Panesso D, Singh KV, Arias CA. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012; 56:3917-22.
55. Wang Y, Li D, Song L, et al. First report of the multiresistance gene cfr in Streptococcus suis. Antimicrob Agents Chemother 2013; 57:4061-3.
56. Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 2012; 194:4494-504.
57. Muraih JK, Pearson A, Silverman J, Palmer M. Oligomerization of daptomycin on membranes. Biochim Biophys Acta 2011; 1808:1154-60.
58. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
59. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26:759-80.
60. Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013; 1277:139-58.
61. Ernst CM, Kuhn S, Slavetinsky CJ, et al. The lipid-modifying multiple peptide resistance factor is an oligomer consisting of distinct interacting synthase and flippase subunits. MBio 2015; 6:e02340-14.
62. Yang SJ, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 2009; 200:1916-20.
63. Peleg AY, Miyakis S,Ward DV, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012; 7:e28316.
64. Mehta S, Cuirolo AX, Plata KB, et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:92-102.
65. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42:1652-3.
66. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892-900.
67. Reyes J, Panesso D, Tran TT, et al. A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis. J Infect Dis 2015; 211:1317-25.
68. Tran TT, Panesso D, Mishra NN, et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 2013; 4:e00281-13.
69. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012; 56:4354-9.
70. Munita JM, Mishra NN, Alvarez D, et al. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis 2014; 59:1277-80.
71. Garcia-de-la-Maria C, Pericas JM, Del Rio A, et al; Hospital Clinic Experimental Endocarditis Study Group. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group streptococci after exposure to daptomycin. Antimicrob Agents Chemother 2013; 57:2319-25.
72. Akins RL, Katz BD, Monahan C, Alexander D. Characterization of high-level daptomycin resistance in viridans group streptococci developed upon in vitro exposure to daptomycin. Antimicrob Agents Chemother 2015; 59:2102-12.
73. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 2010; 54:3161-9.
74. Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin-and cationic host defense peptide-mediated killing of ampicillinand vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56:838-44.
75. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal betalactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158-63.
76. Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014; 58:1494-500.
77. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. Beta-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57:5005-12.
78. Diaz L, Tran TT, Munita JM, et al. Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrob Agents Chemother 2014; 58:4527-34.